Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash & Equivalents (2018 - 2025)

X4 Pharmaceuticals' Cash & Equivalents history spans 8 years, with the latest figure at $217.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 289.68% year-over-year to $217.0 million; the TTM value through Dec 2025 reached $217.0 million, up 289.68%, while the annual FY2025 figure was $217.0 million, 289.68% up from the prior year.
  • Cash & Equivalents reached $217.0 million in Q4 2025 per XFOR's latest filing, up from $69.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $217.0 million in Q4 2025 to a low of $39.2 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $93.6 million, with a median of $87.6 million recorded in 2021.
  • The largest YoY upside for Cash & Equivalents was 289.68% in 2025 against a maximum downside of 73.36% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $81.8 million in 2021, then surged by 48.82% to $121.7 million in 2022, then decreased by 18.49% to $99.2 million in 2023, then tumbled by 43.86% to $55.7 million in 2024, then soared by 289.68% to $217.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Cash & Equivalents are $217.0 million (Q4 2025), $69.6 million (Q3 2025), and $39.2 million (Q2 2025).